1Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature, 2004, 428 ( 6982 ):486.
2Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J, 2006, 6 ( 4 ) : 265-268.
3French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int, 2006, 55 (1): 9-16.
4Hung SI, Chung WH, Liou LB, et al. HLA-B^*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A, 2005, 102 ( 11 ) : 4134-4139.
5Paquet P, Pierard GE, Quatresooz P. Novel treatments for drug-induced toxic epidermal necrolysis ( Lyelrs syndrome ). Int Arch Allergy Immunol, 2005, 136( 3 ) : 205-216.
6Devi K, George S, Criton S, et al. Carbamazepine--the commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: a study of 7 years. Indian J Dermatol Venereol Leprol, 2005, 71 ( 5 ) : 325-328.
7Nakajima T, Yamanoshita O, Kamijima M, et al. Generalized skin reactions in relation to trichloroethylene exposure: a review from the viewpoint of drug-metabolizing enzymes. J Occup Health, 2003, 45 ( 1 ) : 8-14.
8Chave TA, Mortimer NJ, Sladden M J, et al. Toxic epidermal necrolysis: current evidence, practical management and future directions. BrJ Dermatol, 2005, 153 ( 2 ) : 241-253.
9Nassif A, Moslehi H, Le Gouvello S, et al. Evaluation of the potential role ofcytokines in toxic epidermal necrolysis. J Invest Dermatol, 2004, 123 ( 5 ) : 850-855.
10French LE, Trent JT, Kerdel FA. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding, Int Immunopharmacol, 2006, 6 ( 4 ) : 543-549.
